These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 34330647)

  • 1. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editor's Choice - Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD.
    Aboyans V; Morboeuf O; Grenier B; Jolivel R; Bura-Riviere A
    Eur J Vasc Endovasc Surg; 2024 Jun; 67(6):969-978. PubMed ID: 38316351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
    Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N
    Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
    JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
    Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
    Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban in Peripheral Artery Disease after Revascularization.
    Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
    N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
    Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
    J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
    Darmon A; Bhatt DL; Elbez Y; Aboyans V; Anand S; Bosch J; Branch KR; Connolly SJ; Dyal L; Eikelboom JW; Fox KAA; Keltai K; Probstfield J; Yusuf S; Abtan J; Sorbets E; Eagle KA; Ducrocq G; Steg PG
    Eur Heart J; 2018 Mar; 39(9):750-757a. PubMed ID: 29186454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
    Bauersachs RM; Szarek M; Brodmann M; Gudz I; Debus ES; Nehler MR; Anand SS; Patel MR; Hess CN; Capell WH; Rogers K; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP;
    J Am Coll Cardiol; 2021 Jul; 78(4):317-326. PubMed ID: 34010631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
    Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR
    Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
    Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
    Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
    Morrison JT; Canonico ME; Anand SS; Patel MR; Debus ES; Nehler MR; Hess CN; Hsia J; Capell WH; Muehlhofer E; Haskell LP; Berkowitz SD; Bauersachs RM; Bonaca MP
    Circulation; 2024 May; 149(19):1536-1539. PubMed ID: 38709838
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    Krantz MJ; Debus SE; Hsia J; Patel MR; Anand SS; Nehler MR; Hess CN; Capell WH; Bracken T; Szarek M; Mátyás L; Krievins DK; Nault P; Stefanov S; Haskell LP; Berkowitz SD; Muehlhofer E; Hiatt WR; Bauersachs RM; Bonaca MP
    Eur Heart J; 2021 Oct; 42(39):4040-4048. PubMed ID: 34430972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Debus ES; Nehler MR; Govsyeyev N; Bauersachs RM; Anand SS; Patel MR; Fanelli F; Capell WH; Brackin T; Hinterreiter F; Krievins D; Nault P; Piffaretti G; Svetlikov A; Jaeger N; Hess CN; Sillesen HH; Conte M; Mills J; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR; Bonaca MP
    Circulation; 2021 Oct; 144(14):1104-1116. PubMed ID: 34380322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Govsyeyev N; Nehler M; Conte MS; Debus S; Chung J; Dorigo W; Gudz I; Krievins D; Mills J; Moll F; Norgren L; Piffaretti G; Powell R; Szalay D; Sillesen H; Wohlauer M; Szarek M; Bauersachs RM; Anand SS; Patel MR; Capell WH; Jaeger N; Hess CN; Muehlhofer E; Haskell LP; Berkowitz SD; Bonaca MP
    J Vasc Surg; 2023 Apr; 77(4):1107-1118.e2. PubMed ID: 36470531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.